Indications and management of implantable cardioverter-defibrillator therapy in childhood hypertrophic cardiomyopathy: A position statement from the AEPC Working …

JP Kaski, JAE Kammeraad, NA Blom… - Cardiology in the …, 2023 - cambridge.org
Sudden cardiac death is the most common mode of death during childhood and
adolescence in hypertrophic cardiomyopathy, and identifying those individuals at highest …

A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy

G Norrish, T Ding, E Field, K McLeod, M Ilina… - EP …, 2019 - academic.oup.com
Aims Sudden cardiac death (SCD) is the most common cause of death in children with
hypertrophic cardiomyopathy (HCM). The European Society of Cardiology (ESC) …

[HTML][HTML] Risk stratification in childhood hypertrophic cardiomyopathy

G Norrish, JP Kaski - Global Cardiology Science & Practice, 2018 - ncbi.nlm.nih.gov
The true prevalence of hypertrophic cardiomyopathy (HCM) in childhood is unknown, but
population-based studies have reported an annual incidence between 0.24–0.47 per …

Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy

BJ Maron, P Spirito, MJ Ackerman, SA Casey… - Journal of the American …, 2013 - jacc.org
Objectives: The aim of this study was to determine the efficacy of implantable cardioverter-
defibrillators (ICDs) in children and adolescents with hypertrophic cardiomyopathy (HCM) …

Sudden cardiac death in childhood hypertrophic cardiomyopathy

K Thakkar, AR Karajgi, AM Kallamvalappil, C Avanthika… - Disease-a-Month, 2023 - Elsevier
The most prevalent cause of mortality in children with hypertrophic cardiomyopathy (HCM) is
sudden cardiac death (SCD), which happens more frequently than in adult patients. Risk …

Management of arrhythmias in hypertrophic cardiomyopathy

JT Stewart, WJ McKenna - Cardiovascular drugs and therapy, 1994 - Springer
In the management of hypertrophic cardiomyopathy the goals should be the control of
symptoms, and the identification and treatment of those at high risk. Arrhythmias, particularly …

Hypertrophic cardiomyopathy in children, adolescents, and young adults associated with low cardiovascular mortality with contemporary management strategies

BJ Maron, EJ Rowin, SA Casey, JR Lesser… - Circulation, 2016 - Am Heart Assoc
Background—Youthful age has been considered the time of greatest risk for patients with
hypertrophic cardiomyopathy (HCM), largely because of the possibility of sudden death. The …

Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy

JP Kaski, MTT Esteban, M Lowe, S Sporton, P Rees… - Heart, 2007 - heart.bmj.com
METHODS Between 1993 and February 2006, 160 consecutively referred patients with
HCM (age⩽ 16 years) underwent clinical evaluation using 12-lead ECG, two-dimensional, M …

Risk stratification in pediatric hypertrophic cardiomyopathy: Insights for bridging the evidence gap?

SJ Nakano, SC Menon - Progress in pediatric cardiology, 2018 - Elsevier
Identification of children with hypertrophic cardiomyopathy (HCM) who are at high risk for
sudden cardiac death (SCD) remains challenging. Although a large number of risk factors …

[HTML][HTML] Efficacy of implantable cardioverter–defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy

BJ Maron, WK Shen, MS Link, AE Epstein… - … England Journal of …, 2000 - Mass Medical Soc
Background Hypertrophic cardiomyopathy is a genetic disease associated with a risk of
ventricular tachyarrhythmias and sudden death, especially in young patients. Methods We …